Antimicrobial medicines are vital to the treatment of infections such as tuberculosis and pneumonia. Recent trends in the resistance to these medicines are worrying and, if these continue could pose a serious threat to the public health and modern medicine.
The ABPI has raised concerns over this issue, most recently to the Department of Health in our response to their consultation on the Antimicrobial Resistance Strategy. We have been disappointed by the delays in publishing the strategy and hope that it will be published soon.
We hope that the Department of Health will take on board our concerns about the research and development environment and stewardship of antibiotics when they publish the final version of the strategy. We look forward to working in partnership with them and our member companies to find solutions as soon as possible to this important issue.
ABPI Press OfficeTel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811 Email: [email protected]
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.